---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-062458"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2026-05-29T12:42:42+00:00"
generated_at: "2026-05-29T12:45:27.613028+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis

## Summary
- Net loss of approx. $963K ($0.15 per share) for Q1 ended March 31, 2026.
- Cash and equivalents $8.8M, up from $5.0M at Dec 31, 2025; no debt or toxic financing.
- In-licensed two selective JAK inhibitor assets from Impetis Biosciences (TATA Enterprise) for global ~$57B market.
- Filed Orphan Drug Designation application for VT-1953 with FDA; submitted proposals for pivotal development guidance.
- Raised $5.29M via sale of 1,089,545 shares at $5.00 (59.2% premium to prior close); ~15% dilution.

## SEC filing metadata
- accession: 0001213900-26-062458
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2026-05-29T12:42:42+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000121390026062458/0001213900-26-062458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000121390026062458/ea0292643-8k_vyome.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-062458
- JSON: https://secwatch.observer/filing/0001213900-26-062458.json
- Plain text: https://secwatch.observer/filing/0001213900-26-062458.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.